Fibro Daily

Tasimelteon Passes Second Stage Trial; Shows Promise as a Treatment for Rare Sleep Disorder

Fibro Daily January 23, 2013

Tasimelteon, an experimental drug created to treat a rare sleep disorder called non-24-hour sleep-wake disorder (non-24), passed its second late-stage trial. The results were reported as being surprisingly good.

Non-24 is a rare, cicardian rhythm sleep disorder. It causes hourly delays in sleep onset and wake times.

Read more:

Vanda’s Sleep Disorder Drug Tasimelteon Shows Promise Editor’s Choice



Powered by Facebook Comments

Tagged with:

Comments are closed.

Login to your account

Can't remember your Password ?

Register for this site!